Enzon Pharmaceuticals (ENZN) 10-Q 5 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 05, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	000-12957
Entity Registrant Name	Enzon Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-2372868
Entity Address, Address Line One	20 Commerce Drive (Suite 135)
Entity Address, City or Town	Cranford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07016
City Area Code	732
Local Phone Number	980-4500
Title of 12(b) Security	None
No Trading Symbol Flag	true
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,214,603
Entity Central Index Key	0000727510
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 46,633	$ 47,012
Other current assets	337	331
Total current assets	46,970	47,343
Deferred tax asset	306	359
Total assets	47,276	47,702
Current liabilities:
Accounts payable	331	331
Accrued expenses and other current liabilities	107	108
Dividends payable on Series C preferred stock		1,275
Total current liabilities	438	1,714
Commitments and contingencies
Stockholders' equity:
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at September 30, 2024 and December 31, 2023
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at September 30, 2024 and December 31, 2023	742	742
Additional paid-in capital	71,840	73,433
Accumulated deficit	(69,820)	(70,670)
Total stockholders' equity	2,762	3,505
Total liabilities, mezzanine equity and stockholders' equity	47,276	47,702
Mezzanine Equity - Series C Preferred Stock
Mezzanine equity:
Series C preferred stock - $0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value $1,089 and $1,062 per share) at September 30, 2024 and December 31, 2023	$ 44,076	$ 42,483

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Mezzanine equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,960,000	2,960,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	74,214,603	74,214,603
Common stock, shares outstanding	74,214,603	74,214,603
Mezzanine Equity - Series C Preferred Stock
Mezzanine equity
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Shares, shares authorized	40,000	40,000
Preferred stock, shares issued	40,000	40,000
Preferred stock, shares outstanding	40,000	40,000
Preferred stock, liquidation value (in dollars per share)	$ 1,089	$ 1,062

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
License fees			$ 26,000
Total revenues			26,000
Operating expenses:
General and administrative	$ 351,000	$ 225,000	1,028,000	$ 828,000
Total operating expenses	351,000	225,000	1,028,000	828,000
Operating loss	(351,000)	(225,000)	(1,002,000)	(828,000)
Interest and dividend income	654,000	622,000	1,906,000	1,622,000
Income before income tax expense	303,000	397,000	904,000	794,000
Income tax expense	(49,000)	(76,000)	(54,000)	(93,000)
Net income	254,000	321,000	850,000	701,000
Accretion of dividend on Series C preferred stock	(531,000)	(531,000)	(1,593,000)	(1,593,000)
Net loss available to common stockholders	$ (277,000)	$ (210,000)	$ (743,000)	$ (892,000)
Loss per common share
Basic (in dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Diluted (in dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted-average number of shares - basic (in shares)	74,215	74,215	74,215	74,215
Weighted-average number of shares - diluted (in shares)	74,215	74,215	74,215	74,215

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Mezzanine Equity - Series C Preferred Stock Preferred Stock	Mezzanine Equity - Series C Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2022			$ 742	$ 74,708	$ (72,043)	$ 3,407
Balance at the beginning (in shares) at Dec. 31, 2022			74,215,000
Net income					197	197
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Mar. 31, 2023			$ 742	74,177	(71,846)	3,073
Balance at the ending (in shares) at Mar. 31, 2023			74,215,000
Balance at the beginning at Dec. 31, 2022	$ 42,483
Balance at the beginning (in shares) at Dec. 31, 2022	40,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Mar. 31, 2023	$ 43,014
Balance at the ending (in shares) at Mar. 31, 2023	40,000
Balance at the beginning at Dec. 31, 2022			$ 742	74,708	(72,043)	3,407
Balance at the beginning (in shares) at Dec. 31, 2022			74,215,000
Net income						701
Balance at the ending at Sep. 30, 2023			$ 742	73,115	(71,342)	2,515
Balance at the ending (in shares) at Sep. 30, 2023			74,215,000
Balance at the beginning at Dec. 31, 2022	$ 42,483
Balance at the beginning (in shares) at Dec. 31, 2022	40,000
Balance at the ending at Sep. 30, 2023	$ 44,076
Balance at the ending (in shares) at Sep. 30, 2023	40,000
Balance at the beginning at Mar. 31, 2023			$ 742	74,177	(71,846)	3,073
Balance at the beginning (in shares) at Mar. 31, 2023			74,215,000
Net income					183	183
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Jun. 30, 2023			$ 742	73,646	(71,663)	2,725
Balance at the ending (in shares) at Jun. 30, 2023			74,215,000
Balance at the beginning at Mar. 31, 2023	$ 43,014
Balance at the beginning (in shares) at Mar. 31, 2023	40,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Jun. 30, 2023	$ 43,545
Balance at the ending (in shares) at Jun. 30, 2023	40,000
Net income					321	321
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Sep. 30, 2023			$ 742	73,115	(71,342)	2,515
Balance at the ending (in shares) at Sep. 30, 2023			74,215,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Sep. 30, 2023	$ 44,076
Balance at the ending (in shares) at Sep. 30, 2023	40,000
Balance at the beginning at Dec. 31, 2023			$ 742	73,433	(70,670)	3,505
Balance at the beginning (in shares) at Dec. 31, 2023			74,215,000
Net income					320	320
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Mar. 31, 2024			$ 742	72,902	(70,350)	3,294
Balance at the ending (in shares) at Mar. 31, 2024			74,215,000
Balance at the beginning at Dec. 31, 2023	$ 42,483	$ 42,483
Balance at the beginning (in shares) at Dec. 31, 2023	40,000	40,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Mar. 31, 2024	$ 43,014
Balance at the ending (in shares) at Mar. 31, 2024	40,000
Balance at the beginning at Dec. 31, 2023			$ 742	73,433	(70,670)	3,505
Balance at the beginning (in shares) at Dec. 31, 2023			74,215,000
Net income						850
Balance at the ending at Sep. 30, 2024			$ 742	71,840	(69,820)	2,762
Balance at the ending (in shares) at Sep. 30, 2024			74,215,000
Balance at the beginning at Dec. 31, 2023	$ 42,483	$ 42,483
Balance at the beginning (in shares) at Dec. 31, 2023	40,000	40,000
Balance at the ending at Sep. 30, 2024	$ 44,076	$ 44,076
Balance at the ending (in shares) at Sep. 30, 2024	40,000	40,000
Balance at the beginning at Mar. 31, 2024			$ 742	72,902	(70,350)	3,294
Balance at the beginning (in shares) at Mar. 31, 2024			74,215,000
Net income					276	276
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Jun. 30, 2024			$ 742	72,371	(70,074)	3,039
Balance at the ending (in shares) at Jun. 30, 2024			74,215,000
Balance at the beginning at Mar. 31, 2024	$ 43,014
Balance at the beginning (in shares) at Mar. 31, 2024	40,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Jun. 30, 2024	$ 43,545
Balance at the ending (in shares) at Jun. 30, 2024	40,000
Net income					254	254
Preferred stock dividend accretion				(531)		(531)
Balance at the ending at Sep. 30, 2024			$ 742	$ 71,840	$ (69,820)	$ 2,762
Balance at the ending (in shares) at Sep. 30, 2024			74,215,000
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock dividend accretion	$ 531
Balance at the ending at Sep. 30, 2024	$ 44,076	$ 44,076
Balance at the ending (in shares) at Sep. 30, 2024	40,000	40,000

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 254,000	$ 320,000	$ 321,000	$ 197,000	$ 850,000	$ 701,000
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Deferred income taxes	50,000		76,000		53,000	91,000
Changes in operating assets and liabilities					(7,000)	58,000
Net cash provided by operating activities					896,000	850,000
Cash flows from financing activities:
Preferred stock dividend payments					(1,275,000)	(1,275,000)
Net cash used in financing activities					(1,275,000)	(1,275,000)
Net decrease in cash and cash equivalents					(379,000)	(425,000)
Cash and cash equivalents, beginning of period		$ 47,012,000		$ 46,982,000	47,012,000	46,982,000
Cash and cash equivalents, end of period	$ 46,633,000		$ 46,557,000		46,633,000	46,557,000
Non-cash financing activities:
Accretion of dividend for Series C Preferred Stock					$ 1,593,000	$ 1,593,000

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Description of Business
Description of Business	(1) Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the “Company,” “Enzon,” “we” or “us”) is positioned as a public company acquisition vehicle, where it can become an acquisition platform and potentially utilize its net operating loss carryforwards (“NOLs”) in an effort to enhance stockholder value. In September 2020, the Company initiated a rights offering for its common and preferred stock (see below and Note 12 to the Condensed Consolidated Financial Statements), which closed in October 2020, and it realized $43.6 million in gross proceeds. This has enabled the Company to embark on its plan to potentially realize the value of its more than $100 million NOLs by acquiring businesses or assets. To protect the NOLs, in August 2020, the Company’s Board of Directors (the “Board”) adopted a Section 382 rights plan (See Note 11 to the Condensed Consolidated Financial Statements). Historically, the Company had received royalty revenues from licensing arrangements with other companies primarily related to the sales of certain drug products that utilized Enzon’s proprietary technology. In recent years, the Company has had no clinical operations and limited corporate operations. Enzon has a marketing agreement for the drug Vicineum, which, if approved, would, potentially, generate milestone and royalty payments to it in the future. Enzon cannot assure you that it will earn material future royalties or milestones. The Board and the Company’s management are actively involved in pursuing, sourcing, reviewing and evaluating various potential acquisition transactions consistent with its strategy. The Company’s management and Board have made a number of contacts and engaged in discussions with principals of individual companies and financial advisors on behalf of various individual companies, while continuing to evaluate potential transactions. To date, no acquisition candidates have been identified that are in an actionable state. The Company has a marketing agreement with Micromet AG, now part of Amgen, Inc. (the “Micromet Agreement”), pursuant to which it may be entitled to certain milestone and royalty payments if Vicineum, a drug that was being developed by Sesen, Inc., (“Sesen”) is approved for the treatment of non-muscle invasive bladder cancer. Sesen announced that it had completed a merger with Carisma Therapeutics Inc. (“Carisma”), had paused further development of Vicineum in the United States, and had withdrawn its application to market Vicineum in Europe. Sesen also announced that the combined company will focus on the advancement of Carisma’s proprietary cell therapy for the treatment of cancer and other disorders, and it intends to seek a partner for any further development of Vicineum. The Company receives an annual license maintenance fee of approximately $26,000 from Amgen, Inc. in payment of a worldwide, royalty-free non-exclusive right to license Vicineum. The fee represents half of the amount paid by Viventia Biotech (Barbados) Inc. (“Viventia”), part of Sesen, on an annual basis for the continued right to license Vicineum. The Company received the license maintenance fee during the second quarter of 2024. In August 2020, the Board adopted a Section 382 rights plan and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on August 24, 2020. (See Note 11 to the Condensed Consolidated Financial Statements.) In September 2020, the Board approved a Rights Offering (the “Rights Offering”), by which the Company distributed, at no charge to all holders of its common stock on September 23, 2020 (the “Record Date”), transferable subscription rights to purchase units (“Units”) at a subscription price per Unit of $1,090. In the Rights Offering, each stockholder on the Record Date received one subscription right for every share of common stock owned on the Record Date. For every 1,105 subscription rights held, a stockholder was entitled to purchase one Unit at the subscription price. Each Unit consisted of one share of newly designated Series C Preferred Stock, par value $0.01 per share, and 750 shares of the Company’s common stock. The subscription period for the Rights Offering ended on October 9, 2020. As a result of the sale of all 40,000 Units available for purchase in the Rights Offering, the Company received approximately $43.6 million of gross proceeds and had 40,000 shares of Series C Preferred Stock outstanding and an aggregate of 74,214,603 shares of common stock outstanding following the Rights Offering. (See Note 12 to the Condensed Consolidated Financial Statements.) (1) Description of Business (continued) On an annual basis, the Board may, at its sole discretion, cause a dividend with respect to the Series C Preferred Stock to be paid in cash to the holders in an amount equal to 3% of the liquidation preference as in effect at such time (initially $1,000 per share). If the dividend is not so paid in cash, the liquidation preference is adjusted and increased annually by an amount equal to 5% of the liquidation preference per share as in effect at such time, that is not paid in cash to the holders on such date. The Board did not declare a dividend as of December 31, 2021 and, at December 31, 2021 the liquidation value of the Series C Preferred Stock was $1,062 per share. On December 29, 2022, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating $1,275,000 or $31.86 per share. Accordingly, the cumulative liquidation value of the Series C Preferred Stock remained at approximately $42,483,000 ($1,062 per share) on December 31, 2022. On December 28, 2023, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating approximately $1,275,000 or $31.86 per share. Accordingly, the cumulative liquidation value of the Series C Preferred Stock remained at approximately $42,483,000 ($1,062 per share) on December 31, 2023. The dividend was paid on January 17, 2024 to the holders of record of the Company’s Series C Preferred Stock as of January 10, 2024. (See Note 13 to the Condensed Consolidated Financial Statements.) As of September 30, 2024, the Board had not yet determined whether to declare a cash dividend at the end of 2024. Accordingly, the Company accrued an accretion at 5% for the nine-month period on a pro rata basis (approximately $1,593,000 or $40 per share) and, as a result, the liquidation value of the Series C Preferred Stock was approximately $44,076,000 ($1,102 per share) at September 30, 2024. (See Note 13 to the Condensed Consolidated Financial Statements.) The Company maintains its principal executive offices at 20 Commerce Drive, Suite 135, Cranford, New Jersey 07016 through a service agreement with Regus Management Group, LLC.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Basis of Presentation
Basis of Presentation	(2) Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K and Amendment No. 1 to the Company’s Annual Report on Form 10- K for the year ended December 31, 2023. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. (2) Revenue Recognition Royalty revenues from the Company’s agreements with third parties and pursuant to the sale of the Company’s former specialty pharmaceutical business are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. Because the Company records revenue only when collection is assured, no provision for uncollectible accounts is established upon recognition of revenues. Contingent payments with third parties and pursuant to the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured, such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2024
Recent Accounting Pronouncements
Recent Accounting Pronouncements	(3) Recent Accounting Pronouncements Recent Accounting Standards Updates issued by the Financial Accounting Standards Board (the “FASB”) and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future condensed consolidated financial statements.

Financial Instruments and Fair

Financial Instruments and Fair Value	9 Months Ended
	Sep. 30, 2024
Financial Instruments and Fair Value
Financial Instruments and Fair Value	(4) The carrying values of cash and cash equivalents, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s condensed consolidated balance sheets approximated their fair values at September 30, 2024 and December 31, 2023 due to their short-term nature. As of each of September 30, 2024 and December 31, 2023, the Company held cash equivalents aggregating approximately $46.6 million and $47.0 million, respectively.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2024
Supplemental Cash Flow Information
Supplemental Cash Flow Information	(5) The Company made no income tax payments during each of the nine-month periods ended September 30, 2024 and 2023. There were no interest payments made during either of the nine-month periods ended September 30, 2024 or 2023.

Cash Dividend

Cash Dividend	9 Months Ended
	Sep. 30, 2024
Cash Dividend
Cash Dividend	(6) On December 28, 2023, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating approximately $1,275,000 or $31.86 per share. Accordingly, the cumulative liquidation value of the Series C Preferred Stock was approximately $42,483,000 ($1,062 per share) on December 31, 2023. The dividend was paid on January 17, 2024 to the holders of record of the Company’s Series C Preferred Stock as of January 10, 2024 (See Note 13 to the Condensed Consolidated Financial Statements). (6) On December 29, 2022, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating approximately $1,275,000 or $31.86 per share. Accordingly, the cumulative liquidation value of the Series C Preferred Stock was approximately $42,483,000 ($1,062 per share) on December 31, 2022. The dividend was paid on January 17, 2023 to the holders of record of the Company’s Series C Preferred Stock as of January 10, 2023 (See Note 13 to the Condensed Consolidated Financial Statements).

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Sep. 30, 2024
Loss Per Common Share
Loss Per Common Share	(7) Basic earnings (loss) per common share “(EPS)” is calculated by dividing net income (loss), less any dividends, accretion or reduction or redemption on the Company’s Series C Preferred Stock, by the weighted average number of common shares outstanding during the reported period. Restricted stock awards and restricted stock units (collectively, “nonvested shares”) are not considered to be outstanding shares until the service or performance vesting period has been completed. The diluted earnings per common share calculation would normally involve adjusting both the denominator and numerator as described here if the effect is dilutive. For purposes of calculating diluted earnings per common share, the denominator normally includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan. During each of the quarters ended September 30, 2024 and 2023, there were no common stock equivalents. There were no stock options or other equity-based incentives outstanding in either such period. Loss per common share information is as follows (in thousands, except per share amounts) for the three and nine-month periods ended September 30, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Nine months ended ​ ​ September 30, ​ September 30, ​ 2024 2023 2024 2023 Loss Per Common Share – Basic and Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income ​ $ 254 ​ $ 321 ​ $ 850 ​ $ 701 Accretion of dividend on Series C preferred stock ​ ​ (531) ​ ​ (531) ​ ​ (1,593) ​ ​ (1,593) Net loss available to common stockholders ​ $ (277) ​ $ (210) ​ ​ (743) ​ $ (892) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average number of common shares outstanding ​ 74,215 ​ ​ 74,215 ​ ​ 74,215 ​ ​ 74,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted loss per common share ​ $ (0.00) ​ $ (0.00) ​ $ (0.01) ​ $ (0.01) ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes
Income Taxes	(8) During the nine-month period ended September 30, 2024 the Company recorded approximately $54,000 of income tax expense. During the comparable period in 2023, the Company recorded approximately $93,000 of income tax expense. The income tax expense in 2024 was mainly related to the reduction of the net deferred tax asset due to the utilization of federal and state net operating loss carryforwards. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Because of the inherent uncertainties, including future interest rates, whether or when an acquisition of a profitable entity will come to fruition and other factors, projecting long-term future performance of the Company is problematical. Accordingly, the Company is only projecting pre-tax book income through September 30, 2025 due to interest rates on its short-term cash investments and the absence of any potentially actionable acquisitions at this time. Upon review of positive and negative evidence in determining a partial reversal of the valuation allowance, the Company has concluded that a partial reversal of the valuation allowance is necessary. Interest rates may fluctuate throughout the period through September 30, 2025. However, the Company does not expect them to return to low rates of the past creating a projected taxable income position. Accordingly, a deferred tax expense of approximately $50,000 and $76,000 was recorded during the quarters ended September 30, 2024 and 2023, respectively. The Company may acquire businesses, entities or revenue streams that could generate sufficient income so that it can utilize its approximately $101.6 million NOL. To date, no acquisition candidates have been identified that are in an actionable state and, while the Company may ultimately be successful in realizing some or all of the value of its NOLs, the Company cannot provide assurance that it will be able to realize any value of its NOLs. Management of the Company will continue to assess the need for this valuation allowance and will make adjustments when or if appropriate. At September 30, 2024, the Company had federal NOLs of approximately $101.6 million, of which approximately $98.5 million will expire in the years 2025 through 2036, and New Jersey state NOLs of approximately $23.9 million that expire in the years 2031 through 2042. Under the Tax Cuts and Jobs Act, net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income. At September 30, 2024, the Company has federal research and development (“R&D”) credit carryforwards of approximately $9.4 million that expire in the years 2024 through 2029. These deferred tax assets were subject to a valuation allowance such that the deferred tax expense incurred as a result of the expiration of the R&D credit carryforwards was offset by a corresponding deferred tax benefit for the related reduction in valuation allowance. The Company’s ability to use the NOLs and R&D tax credit carryforwards may be limited, as they are subject to certain limitations due to ownership changes as defined by rules pursuant to Section 382 of the Internal Revenue Code of 1986, as amended. However, management of the Company believes that the Company’s NOLs will not be limited by any changes in the Company’s ownership as a result of the successful completion of the Rights Offering. (See Note 12 to the Condensed Consolidated Financial Statements.) Additionally, in an effort to protect stockholder value by attempting to protect against a possible limitation on the Company’s ability to use its NOLs, the Board adopted a Section 382 rights plan. (See Note 11 to the Condensed Consolidated Financial Statements.) The Company has not recorded a liability for unrecognized income tax benefits.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2024
Commitments and Contingent Liabilities
Commitments and Contingent Liabilities	(9) The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s condensed consolidated financial position, results of operations, or liquidity.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	(10) Prior to 2017, the Company’s primary source of royalty revenues was derived from sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). At December 31, 2023, the Company recorded a liability to Merck of approximately $331,000, based primarily on Merck’s assertions regarding recoupments related to prior returns and rebates. Merck has not yet reported 2024 royalty revenue earned by the Company for product sales and/or recoupments for returns and rebates. Accordingly, at September 30, 2024, the Company recorded a net payable to Merck of approximately $331,000 due to such royalty overpayment claims by Merck. The Company believes that it will receive no additional royalties from Merck, as all of the relevant patents have expired. Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2024 2023 Professional and consulting fees ​ $ 101 ​ $ 92 Other ​ ​ 6 ​ ​ 16 ​ ​ $ 107 ​ $ 108 ​

Section 382 Rights Plan

Section 382 Rights Plan	9 Months Ended
	Sep. 30, 2024
Section 382 Rights Plan
Section 382 Rights Plan	(11) On August 14, 2020, in an effort to protect stockholder value by attempting to protect against a possible limitation on the Company’s ability to use its NOLs, the Board adopted a Section 382 rights plan and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on August 24, 2020. Accordingly, holders of the Company’s common stock own one preferred stock purchase right for each share of common stock owned by such holder. The rights are not immediately exercisable and will become exercisable only upon the occurrence of certain events as set forth in the Section 382 rights plan. If the rights become exercisable, each right would initially represent the right to purchase from the Company one

Rights Offering

Rights Offering	9 Months Ended
	Sep. 30, 2024
Rights Offering
Rights Offering	(12) On September 1, 2020, the Board approved a Rights Offering. For every 1,105 subscription rights held, a stockholder was entitled to purchase one Unit at the subscription price of $1,090. Each Unit consisted of one share of newly designated Series C Preferred Stock, par value $0.01 per share, and 750 shares of the Company’s common stock. On October 9, 2020, the Rights Offering expired and, as a result of the sale of all 40,000 Units, the Company received approximately $43.6 million in gross proceeds and issued shares of Series C Preferred Stock and shares of common stock such that, following the closing of the Rights Offering, there was an aggregate of 40,000 shares of Series C Preferred Stock outstanding and 74,214,603 shares of common stock outstanding. (12) On an annual basis, the Board may, at its sole discretion, cause a dividend with respect to the Series C Preferred Stock to be paid in cash to the holders in an amount equal to 3% of the liquidation preference as in effect at such time (initially $1,000 per share). If the dividend is not so paid in cash, the liquidation preference is adjusted and increased annually by an amount equal to 5% of the liquidation preference per share as in effect at such time, that is not paid in cash to the holders on such date. Holders of Series C Preferred Stock do not have any voting rights and the Series C Preferred Stock is not convertible into shares of the Company’s common stock. The initial liquidation value of the Series C Preferred Stock was $1,000 per share. At December 31, 2021 the liquidation value of the Series C Preferred Stock was $1,062 per share, inasmuch as no dividend was declared or paid in cash. On December 29, 2022, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating approximately $1,275,000 or $31.86 per share. Accordingly, the liquidation value of the Series C Preferred Stock was $1,062 per share on December 31, 2022. The dividend was paid on January 17, 2023 to the holders of record of the Company’s Series C Preferred Stock as of January 10, 2023. On December 28, 2023, the Board declared a cash dividend of 3% on the Series C Preferred Stock, aggregating approximately $1,275,000 or $31.86 per share. Accordingly, the liquidation value of the Series C Preferred Stock remained at $1,062 per share on December 31, 2023. The dividend was paid on January 17, 2024 to the holders of record of the Company’s Series C Preferred Stock as of January 10, 2024. Since November 1, 2022, the Company is able to redeem the Series C Preferred Stock at any time, in whole or in part, for an amount based on the liquidation preference per share as in effect at such time. Holders of Series C Preferred Stock have the right to demand that the Company redeem their shares in the event that the Company undergoes a change of control as defined in the Certificate of Designation of the Series C Preferred Stock.

Series C Preferred Stock

Series C Preferred Stock	9 Months Ended
	Sep. 30, 2024
Series C Preferred Stock
Series C Preferred Stock	(13) Series C Preferred Stock In October 2020, the Company issued 40,000 shares of Series C Preferred Stock for an aggregate purchase price of $40.0 million. As of December 31, 2021, the Board had not declared a cash dividend on the Series C Preferred Stock. Accordingly, during the year ended December 31, 2021, the Company recorded a 5% increase to the liquidation preference of approximately $50 per share of Series C Preferred Stock, aggregating approximately $2,023,000, for a cumulative liquidation value of approximately $42,483,000 ($1,062 per share) as of December 31, 2021. Because a cash dividend of 3% was declared for each of 2023 and 2022, at December 31, 2023 and 2022 there was no change to the liquidation value that was recorded as of December 31, 2021. As of September 30, 2024, the Board had not yet determined whether to declare a cash dividend at the end of 2024. Accordingly, the Company accrued an accretion at 5% for the 2024 nine-month period on a pro rata basis (approximately $1,593,000 or $40 per share) and, as a result, the liquidation value of the Series C Preferred Stock was approximately $44,076,000 ($1,102 per share) at September 30, 2024. There is no prohibition on the repurchase or redemption of Series C Preferred Shares while there is any arrearage in the payment of dividends. Since the redemption of the Series C Preferred Stock is contingently or optionally redeemable, unless and until the Company undertakes a change of control, the Series C Preferred Stock has been classified in mezzanine equity on the Company’s Condensed Consolidated Balance Sheets.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents
Cash and Cash Equivalents	(14) Cash and Cash Equivalents The Company defines cash equivalents as highly liquid, short-term investments with original maturities of three months or less. These financial instruments potentially subject the Company to concentrations of credit risk. The Company maintains deposit accounts with several financial institutions. These balances are partially insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per depositor, per FDIC-insured bank, per ownership category. Such deposits may exceed FDIC insurance limits. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the nine-month periods ended September 30, 2024 and 2023 and the year ended December 31, 2023.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 254	$ 276	$ 320	$ 321	$ 183	$ 197	$ 850	$ 701

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2024
Basis of Presentation
Interim Financial Statements	Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K and Amendment No. 1 to the Company’s Annual Report on Form 10- K for the year ended December 31, 2023.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition	Revenue Recognition Royalty revenues from the Company’s agreements with third parties and pursuant to the sale of the Company’s former specialty pharmaceutical business are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. Because the Company records revenue only when collection is assured, no provision for uncollectible accounts is established upon recognition of revenues. Contingent payments with third parties and pursuant to the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured, such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2024
Loss Per Common Share
Schedule of loss per common share	Loss per common share information is as follows (in thousands, except per share amounts) for the three and nine-month periods ended September 30, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Nine months ended ​ ​ September 30, ​ September 30, ​ 2024 2023 2024 2023 Loss Per Common Share – Basic and Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income ​ $ 254 ​ $ 321 ​ $ 850 ​ $ 701 Accretion of dividend on Series C preferred stock ​ ​ (531) ​ ​ (531) ​ ​ (1,593) ​ ​ (1,593) Net loss available to common stockholders ​ $ (277) ​ $ (210) ​ ​ (743) ​ $ (892) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average number of common shares outstanding ​ 74,215 ​ ​ 74,215 ​ ​ 74,215 ​ ​ 74,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted loss per common share ​ $ (0.00) ​ $ (0.00) ​ $ (0.01) ​ $ (0.01) ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Accounts Payable and Accrued Expenses
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2024 2023 Professional and consulting fees ​ $ 101 ​ $ 92 Other ​ ​ 6 ​ ​ 16 ​ ​ $ 107 ​ $ 108 ​

Description of Business (Detail

Description of Business (Details)						1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 28, 2023 USD ($) $ / shares	Dec. 29, 2022 USD ($) $ / shares	Oct. 09, 2020 $ / shares	Sep. 01, 2020 shares	Aug. 14, 2020 shares	Sep. 30, 2020 USD ($) item $ / shares shares	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Sep. 23, 2020 $ / shares
Description of Business
Amount of operating loss carry forward | $								$ 101,600,000
License Maintenance Fee | $							$ 26,000
Common stock, shares outstanding | shares								74,214,603	74,214,603
Rights Offering
Description of Business
Rights offering and realized in gross proceeds | $						$ 43,600,000
Amount of operating loss carry forward | $						$ 100,000,000
Subscription price per Unit												$ 1,090
Number of rights per share of stock | shares				1		1
Number of subscription rights to be held | item						1,105
Number of units entitled for subscription rights held | shares				1		1
Preferred stock, par value						$ 1
Number of units available for purchase | shares						40,000
Rights Offering | Common Stock
Description of Business
Number of shares per unit | shares						750
Common stock, shares outstanding | shares								74,214,603
Section 382 Rights Plan
Description of Business
Rights per share distributed as dividend | shares					1
Series C Preferred Stock
Description of Business
Preferred stock, par value								$ 0.01	$ 0.01
Preferred stock, shares outstanding | shares								40,000	40,000
Percentage of dividend on liquidation preference to be paid in cash								3%
Initial dividend per share								$ 1,000
Percentage of annual increase in liquidation preference								5%
Cash dividend (as percent)	3%	3%						5%
Aggregated dividend amount | $	$ 1,275,000	$ 1,275,000						$ 1,593,000
Preferred stock, liquidation value (in dollars per share)								$ 1,089	$ 1,062	$ 1,062	$ 1,062
Preferred stock, liquidation value | $										$ 42,483,000
Dividend per share	$ 31.86	$ 31.86						$ 40
Preferred stock, cumulative liquidation value | $								$ 44,076,000	$ 42,483,000	$ 42,483,000	$ 2,023,000
Preferred stock, liquidation price (in dollars per share)								$ 1,102	$ 1,062	$ 1,062	$ 1,062
Series C Preferred Stock | Rights Offering
Description of Business
Preferred stock, par value						$ 0.01
Percentage of dividend on liquidation preference to be paid in cash			3%
Preferred stock, liquidation price (in dollars per share)			$ 1,000								$ 1,062

Basis of Presentation (Details)

Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Basis of Presentation
Provision for uncollectible accounts	$ 0
Liability for uncertain tax positions	$ 0

Financial Instruments and Fai_2

Financial Instruments and Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Financial Instruments and Fair Value
Cash and cash equivalents, at carrying value	$ 46.6	$ 47

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplemental Cash Flow Information
Cash paid for income taxes	$ 0	$ 0
Interest paid, net	$ 0	$ 0

Cash Dividend (Details)

Cash Dividend (Details) - Series C Preferred Stock - USD ($)			9 Months Ended
	Dec. 28, 2023	Dec. 29, 2022	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash Dividend
Cash dividend (as percent)	3%	3%	5%
Aggregated dividend amount	$ 1,275,000	$ 1,275,000	$ 1,593,000
Dividend per share	$ 31.86	$ 31.86	$ 40
Preferred stock, cumulative liquidation value			$ 44,076,000	$ 42,483,000	$ 42,483,000	$ 2,023,000
Preferred stock, liquidation price (in dollars per share)			$ 1,102	$ 1,062	$ 1,062	$ 1,062

Loss Per Common Share (Details)

Loss Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Loss Per Common Share - Basic and Diluted:
Net income	$ 254	$ 276	$ 320	$ 321	$ 183	$ 197	$ 850	$ 701
Accretion of dividend on Series C preferred stock	(531)			(531)			(1,593)	(1,593)
Net loss available to common stockholders	$ (277)			$ (210)			$ (743)	$ (892)
Weighted-average number of common shares outstanding - Basic (in shares)	74,215			74,215			74,215	74,215
Weighted-average number of common shares outstanding- Diluted (in shares)	74,215			74,215			74,215	74,215
Loss per common share - Basic (in dollars per share)	$ 0			$ 0			$ (0.01)	$ (0.01)
Loss per common share - Diluted (in dollars per share)	$ 0			$ 0			$ (0.01)	$ (0.01)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Taxes
Income tax expense	$ 49,000	$ 76,000	$ 54,000	$ 93,000
Deferred tax expenses	50,000	$ 76,000	53,000	$ 91,000
Operating loss carryforwards	101,600,000		$ 101,600,000
Tax credit carryforward, limitations on use			Under the Tax Cuts and Jobs Act, net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income.
Domestic Tax Authority
Income Taxes
Operating loss carryforwards	98,500,000		$ 98,500,000
New Jersey state income tax
Income Taxes
Operating loss carryforwards	23,900,000		23,900,000
R & D credit carryforwards | Domestic Tax Authority
Income Taxes
Tax credit carryforwards amount	$ 9,400,000		$ 9,400,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts Payable and Accrued Expenses
Professional and consulting fees	$ 101	$ 92
Other	6	16
Total accrued expenses and other current liabilities	$ 107	$ 108

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Merck
Accounts Payable and Accrued Expenses
Accrued royalties	$ 331,000	$ 331,000

Section 382 Rights Plan (Detail

Section 382 Rights Plan (Details)	Aug. 14, 2020 Vote $ / shares shares	Sep. 30, 2024 $ / shares	Dec. 31, 2023 $ / shares
Section 382 Rights Plan
Preferred stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Section 382 Rights Plan
Section 382 Rights Plan
Rights per share distributed as dividend | shares	1
Number of preferred stock purchase right for each common stockholder | shares	1
Section 382 Rights Plan | Series A-1 Junior Participating Preferred Stock
Section 382 Rights Plan
Number of common stock eligible for each warrant become exercisable | shares	1.001
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01
Purchase price per right (in dollars per share) | $ / shares	$ 1.20
Number of votes for fractional share | Vote	1

Rights Offering (Details)

Rights Offering (Details) - USD ($)					1 Months Ended	9 Months Ended
	Dec. 28, 2023	Dec. 29, 2022	Oct. 09, 2020	Sep. 01, 2020	Sep. 30, 2020	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Rights Offering
Preferred stock, par value (in dollars per share)						$ 0.01	$ 0.01
Preferred stock, shares outstanding						0	0
Common stock, shares outstanding						74,214,603	74,214,603
Rights Offering
Rights Offering
Number of subscription rights to be held for purchase of a unit				1,105
Number of units entitled for subscription rights held				1	1
Subscription price per unit of a right				$ 1,090
Number of common stock eligible for each warrant become exercisable				1	1
Series C Preferred Stock
Rights Offering
Percentage of dividend on liquidation preference to be paid in cash						3%
Cash dividend (as percent)	3%	3%				5%
Aggregated dividend amount	$ 1,275,000	$ 1,275,000				$ 1,593,000
Dividend per share	$ 31.86	$ 31.86				$ 40
Preferred stock, liquidation price (in dollars per share)						$ 1,102	$ 1,062	$ 1,062	$ 1,062
Series C Preferred Stock | Rights Offering
Rights Offering
Preferred stock, par value (in dollars per share)				$ 0.01
Number of common shares for unit				750
Percentage of dividend on liquidation preference to be paid in cash			3%
Preferred stock, liquidation price (in dollars per share)			$ 1,000						$ 1,062
Annual increase in percentage of the liquidation preference per share, if dividend not paid in cash			5%
Investment Agreement | Rights Offering
Rights Offering
Number of units sold			40,000
Issued and gross proceeds			$ 43,600,000
Common stock, shares outstanding			74,214,603
Investment Agreement | Series C Preferred Stock | Rights Offering
Rights Offering
Preferred stock, shares outstanding			40,000

Series C Preferred Stock (Detai

Series C Preferred Stock (Details) - Series C Preferred Stock - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Oct. 31, 2020	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Series C Preferred Stock
Number of shares issued (in shares)		40,000
Aggregate purchase price		$ 40,000,000
Preferred stock, increase in liquidation preference rate (in percentage)	5%		5%
Preferred stock, increase in liquidation preference price (in dollars per share)	$ 50		$ 40
Preferred stock, cumulative liquidation value	$ 42,483,000		$ 1,593,000
Preferred stock, liquidation preference value	$ 2,023,000		$ 44,076,000	$ 42,483,000	$ 42,483,000
Preferred stock, liquidation price (in dollars per share)	$ 1,062		$ 1,102	$ 1,062	$ 1,062
Preferred stock, liquidation preference (in percentage)				3%	3%